# A Study to Evaluate the Effectiveness and Safety of Tapentadol(CG5503) in the Treatment of Acute Pain After Hip Replacement Surgery Compared With Oxycodone and Placebo Followed by a Voluntary Open-Label Extension For Safety

> **NCT00364533** · PHASE3 · TERMINATED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 367 (actual)

## Conditions studied

- Arthroplasty

## Interventions

- **DRUG:** Tapentadol IR (CG5503)
- **DRUG:** Placebo
- **DRUG:** Oxycodone HCL IR
- **DRUG:** Tapentadol IR (CG5503)

## Key facts

- **NCT ID:** NCT00364533
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-10
- **Primary completion:** 2007-12
- **Final completion:** 2007-12
- **Target enrollment:** 367 (ACTUAL)
- **Why stopped:** Slow enrollment
- **Last updated:** 2014-04-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00364533

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00364533, "A Study to Evaluate the Effectiveness and Safety of Tapentadol(CG5503) in the Treatment of Acute Pain After Hip Replacement Surgery Compared With Oxycodone and Placebo Followed by a Voluntary Open-Label Extension For Safety". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00364533. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*